WestGene Biopharma Co., Ltd., a biotechnology company based in Chengdu, has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to proceed with clinical trials for its candidate drug, WGc-043. This marks a significant milestone as WGc-043 is the world’s first mRNA therapeutic vaccine targeting Epstein-Barr (EB) virus-related tumors to be approved for clinical trials.
Designed for the treatment of adult patients with EB virus-positive advanced solid tumors who have completed second-line treatment, as well as adult patients with recurrent or refractory EB virus-positive hematomas, WGc-043 has previously been granted clinical trial approval in the U.S. for similar indications. WestGene has already demonstrated promising results with its drug candidate, having completed an investigator-initiated trial (ITT) for nasopharyngeal carcinoma and natural killer T-cell lymphoma. The trial showcased WGc-043’s superior safety and efficacy compared to other mRNA tumor therapeutic vaccines currently available.- Flcube.com
